Trial Consortium, NEJM, doi:10.1056/NEJMoa2023184 (preprint 10/15) (Peer Reviewed)
WHO SOLIDARITY open-label RCT with 2,750 very late stage (76% on oxygen/ventilation) Remdesivir patients, mortality relative risk RR 0.95 [0.81-1.11], p
Non-ventilated patients show a greater benefit, RR 0.86 [0.72-1.04], p
SOLIDARITY et al., 10/15/2020, Randomized Controlled Trial, multiple countries, multiple regions, peer-reviewed, 15 authors.
risk of death, 5.0% lower, RR 0.95, p = 0.53, treatment 301 of 2743 (11.0%), control 303 of 2708 (11.2%).
non-ventilated patients, 14.0% lower, RR 0.86, p = 0.13.
Effect extraction follows pre-specified rules prioritizing more serious
outcomes. For an individual study the most serious outcome may have a smaller
number of events and lower statistical signficance, however this provides the
strongest evidence for the most serious outcomes when combining the results of